 | NEW VISTAS IN THERAPEUTICS: FROM DRUG DESIGN TO GENE THERAPY
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 953:165-184 (2001)
© 2001 New York Academy of Sciences
DOTS and DOTS-Plus
Not the Only Answer
PAUL FARMER
Infectious Disease Division, Brigham and Women's Hospital and Department of Social Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
Address for correspondence: Paul Farmer, M.D., Ph.D., Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02114. Voice: 617-432-3715; fax: 617-432-6045.
PIHPaul{at}aol.com
Multidrug-resistant tuberculosis is already a global pandemic, with focal "hot spots" of ongoing transmission. Although DOTS (directly observed treatment, short course) chemotherapy is the goal of global tuberculosis control, short-course chemotherapy will not cure multidrug-resistant tuberculosis. In settings of high transmission of multidrug-resistant tuberculosis, "DOTS plus" (a complementary DOTS-based strategy with provisions for treating multidrug-resistant tuberculosis) is warranted. DOTS-plus project implementation to date reveals important clinical, epidemiological, and economic lessons. Community-based strategies designed to enhance local capacity are cost effective and make it possible to meet new medical challenges.
Key Words: multidrug-resistant tuberculosis • DOTS • DOTS-plus • public health • pan-resistant TB • transnational case finding
This article has been cited by other articles:
|
|
|
|
 
H. Mayta, R. H. Gilman, F. Arenas, T. Valencia, L. Caviedes, S. H. Montenegro, E. Ticona, J. Ortiz, R. Chumpitaz, C. A. Evans, et al.
Evaluation of a PCR-Based Universal Heteroduplex Generator Assay as a Tool for Rapid Detection of Multidrug-Resistant Mycobacterium tuberculosis in Peru
J. Clin. Microbiol.,
December 1, 2003;
41(12):
5774 - 5777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med.,
February 15, 2003;
167(4):
603 - 662.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Feng and R. G. Barletta
Roles of Mycobacterium smegmatisD-Alanine:D-Alanine Ligase and D-Alanine Racemase in the Mechanisms of Action of and Resistance to the Peptidoglycan Inhibitor D-Cycloserine
Antimicrob. Agents Chemother.,
January 1, 2003;
47(1):
283 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J M Grange and A Zumla
The global emergency of tuberculosis: what is the cause?
The Journal of the Royal Society for the Promotion of Health,
June 1, 2002;
122(2):
78 - 81.
[Abstract]
[PDF]
|
|
|
|
